NOVEL clpL

Abstract: The invention provides clpL polypeptides and DNA (RNA) encoding clpL polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing clpL polypeptides to screen for antibacterial compounds.

Description: NOVEL clpL RELATED APPLICATIONS This application claims benefit to US Provisional Patent Application Number 60/061,065 filed October 3, 1997 FIELD OF THE INVENTION This invention relates to newly identified polynucleotides and polypeptides. and their production and uses, as well as their variants, agonists and antagonists, and their uses In particular, in these and in other regards, the invention relates to polynucleotides and polypeptides of the Clp ATPases family, hereinafter referred to as "clpL" BACKGROUND OF THE INVENTION The frequency of Staphylococcus aureus infections has risen dramatically in the past 20 years This has been attributed to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems It is no longer uncommon to isolate Staphylococcus aureus strains which are resistant to some or all of the standard antibiotics This has created a demand for both new anti-microbial agents and diagnostic tests for this organism The Clp ATPases constitute a recently discovered family that is represented in every organism examined thus far They appear to serve at least two roles in the cell They are involved in the regulation of proteolysis by activating the ClpP protease in the ATP-dependent cleavage of denatured proteins (Squires & Squires. 1992, The Clp Proteins Proteolysis regulators or molecular chaperones? Journal of Bacteriology 174 1081-5) They are also molecular chaperones which can function independently of ClpP protease, and are capable of repairing proteins damaged during stress conditions (Wawrzynow A , Banecki, B & Zy cz, M , 1996. The Clp ATPases define a novel class of molecular chaperones Molecular Microbiology 21 895-9) Microorganisms such as Staphylococcus aureus are under a variety of environmental stresses in vivo, and it can be expected that members of the Clp ATPase family will play a role in survival and growth of the pathogen during infection Consistent with this is the discovery of a gene encoding a Clp-kke protein which is expressed in vivo Inhibition of the function of this protein is likely to impair the ability of Staphylococcus aureus to establish and maintain an infection Clearly, there is a need for factors, such as the compounds of the invention, that have a present benefit of being useful to screen compounds for antibiotic activity Such factors are also useful to determine their role in pathogenesis of infection, dysfunction and disease There is also a need for identification and characterization of such factors and their antagonists and agonists which can play a role in preventing, ameliorating or correcting infections, dysfunctions or diseases The polypeptides of the invention have amino acid sequence homology to a known Lactococcus lactis clpL protein SUMMARY OF THE INVENTION It is an object of the invention to provide polypeptides that have been identified as clpL polypeptides of the invention by homology between the amino acid sequence set out in Table 1 [SEQ ID NO 2] and a known amino acid sequence or sequences of other proteins such as Lactococcus lactis clpL protein It is a further object of the invention to provide polynucleotides that encode clpL polypeptides particularly polynucleotides that encode the polypeptide herein designated clpL In a particularly preferred embodiment of the invention, the polynucleotide compπses a region encoding clpL polypeptides comprising the sequence set out in Table 1 fSEQ ID NO 1]. or a variant thereof In another particularly preferred embodiment of the invention, there is a clpL protein from Staphylococcus aureus comprising the amino acid sequence of Table 1 [SEQ ID NO 2], or a variant thereof In accordance with another aspect of the invention, there is provided an isolated nucleic acid molecule encoding a mature polypeptide expressible by the Staphylococcus aureus WCUH 29 strain contained in the deposited strain As a further aspect of the invention, there are provided isolated nucleic acid molecules encoding clpL particularly Staphylococcus aureus clpL, including mRNAs, cDNAs. genomic DNAs Further embodiments of the invention include biologically, diagnostically prophylactically. clinically or therapeutically useful variants thereof, and compositions comprising the same In accordance with another aspect of the invention, there is provided the use of a polynucleotide of the invention for therapeutic or prophylactic purposes, m particular genetic unmumzation Among the particularly preferred embodiments of the invention are naturally occurring aliehc variants of clpL and polypeptides encoded thereby As another aspect of the invention, there are provided polypeptides of Staphylococcus aureus referred to herein as clpL as well as biologically, diagnostically. prophylactically, clinically or therapeutically useful variants thereof, and compositions comprising the same Among the particularly preferred embodiments of the invention are variants of clpL polypeptide encoded by naturally occurring alleles of the clpL gene In a preferred embodiment of the invention, there are provided methods for producing the aforementioned clpL polypeptides In accordance with yet another aspect of the invention, there are provided inhibitors to such polypeptides, useful as antibacterial agents, including, for example, antibodies In accordance with certain preferred embodiments of the invention, there are provided products compositions and methods for assessing clpL expression, treatmg disease, for example, disease, such as. infections of the upper respiratory tract (e g , otitis media, bacterial tracheitis, acute epiglottitis thyroiditis), lower respiratory (e g empyema, lung abscess), cardiac (e g , infective endocarditis), gastrointestinal (e g , secretory diarrhoea, splenic abscess, retropeπtoneal abscess), CNS (e g cerebral abscess), eye (e g . blepharitis, conjunctivitis, keratitis. endophthalmitis, preseptal and orbital cellulitis, darcryocystitis), kidney and urinary tract (e g , epididymitis, mtrarenal and pennephric abscess, toxic shock syndrome), skin (e g , impetigo, folkculitis, cutaneous abscesses, cellulitis, wound infection, bacterial myositis) bone and jomt (e g , septic arthritis, osteomyelitis), assaying genetic variation, and administering a clpL polypeptide or polynucleotide to an organism to raise an lmmunological response against a bacteria, especially a Staphylococcus aureus bacteria In accordance with certain preferred embodiments of this and other aspects of the invention, there are provided polynucleotides that hybridize to clpL polynucleotide sequences, particularly under stringent conditions In certain preferred embodiments of the invention, there are provided antibodies against clpL polypeptides In other embodiments of the invention, there are provided methods for identifying compounds which bind to or otherwise interact with and inhibit or activate an activity of a polypeptide or polynucleotide of the mvention comprising contacting a polypeptide or polynucleotide of the invention with a compound to be screened under conditions to permit binding to or other interaction between the compound and the polypeptide or polynucleotide to assess the binding to or other interaction with the compound, such binding or interaction being associated with a second component capable of providing a detectable signal in response to the bmding or interaction of the polypeptide or polynucleotide with the compound, and determining whether the compound binds to or otherwise interacts with and activates or inhibits an activity of the polypeptide or polynucleotide by detecting the presence or absence of a signal generated from the binding or interaction of the compound with the polypeptide or polynucleotide hi accordance with yet another aspect of the invention, there are provided clpL agonists and antagonists, preferably bacteπostatic or bacteπocidal agonists and antagonists In a further aspect of the invention, there are provided compositions comprising a clpL polynucleotide or a clpL polypeptide for administration to a cell or to a multicellular organism Various changes and modifications within the spirit and scope of the disclosed mvention will become readily apparent to those skilled in the art from reading the following descriptions and from reading the other parts of the present disclosure GLOSSARY The followmg definitions are provided to facilitate understanding of certain terms used frequently herein "Host cell" is a cell which has been transformed or transfected, or is capable of transformation or transfection by an exogenous polynucleotide sequence "Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as the case may be, as determined by comparmg the sequences In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences "Identity" can be readily calculated by known methods, mcludmg but not limited to those described m (Computational Molecular Biology, Lesk, A M , ed , Oxford University Press, New York, 1988, Bwcomputmg fnformatics and Genome Projects. Smith, D W , ed , Academic Press, New York. 1993, Computer Analysis of Sequence Data, Part I, Griffin, A M . and Griffin. H G , eds , Humana Press. New Jersey. 1994, Sequence Analysis in Molecular Biology, von Hemje. G , Academic Press, 1987, and Sequence Analysis Primer, Gnbskov, M and Devereux, J , eds , M Stockton Press. New York, 1991, and Caπllo. H . and Lipman. D , SIAM J Applied Math , 48 1073 (1988) Methods to determine identity are designed to give the largest match between the sequences tested Moreover, methods to determine identity are codified in publicly available computer programs Computer program methods to determine identity between two sequences mclude, but are not limited to, the GCG program package (Devereux, J , et al , Nucleic Acids Research 12(1) 387 (1984)). BLASTP, BLASTN, and FASTA (Altschul, S F et al . J Molec Biol 215 403-410 (1990) The BLAST X program is publicly from NCBI and other sources (BLAST Manual. Altschul, S . et al , NCBI NLM NM Bethesda, MD 20894. Altschul, S , et al . J Mol Biol 215 403-410 (1990) The well known Smith Waterman algorithm may also be used to determine identity Parameters for polypeptide sequence comparison include the followmg 1) Algorithm Needleman and Wunsch. J Mol Biol 48 443-453 (1970) Comparison matrix BLOSSUM62 from Hentikoff and Hentikoff, Proc Natl Acad Sci USA 89 10915-10919 (1992) Gap Penalty 12 Gap Length Penalty 4 A program useful with these parameters is publicly available as the "gap" program from Genetics Computer Group, Madison WI The aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps) Parameters for polynucleotide comparison include the followmg 1) Algorithm Needleman and Wunsch, j Mol Biol 48 443-453 (1970) Comparison matrix matches = +10, mismatch = 0 Gap Penalty 50 Gap Length Penalty 3 Available as The "gap" program from Genetics Computer Group, Madison WI These are the default parameters for nucleic acid compaπsons A preferred meaning for "identity" for polynucleotides and polypeptides, as the case may be, are provided in (1) and (2) below (1) Polynucleotide embodiments further mclude an isolated polynucleotide comprising a polynucleotide sequence havmg at least a 50, 60, 70, 80, 85, 90, 95, 97 or 100% identity to the reference sequence of SEQ ID NOS 1 or 3, wherein said polynucleotide sequence may be identical to the reference sequence of SEQ ID NOS 1 or 3 or may mclude up to a certain integer number of nucleotide alterations as compared to the reference sequence, wherein said alterations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides m the reference sequence or in one or more contiguous groups within the reference sequence, and wherein said number of nucleotide alterations is determined by multiplying the total number of nucleotides m SEQ ID NOS 1 or 3 by the integer defining the percent identity divided by 100 and then subtractmg that product from said total number of nucleotides m SEQ ID NOS 1 or 3, or n n ≤ x n " ( x n * y), wherein n n is the number of nucleotide alterations, x n is the total number of nucleotides m SEQ ID NOS 1 or 3. y is 0 50 for 50%, 0 60 for 60%, 0 70 for 70%, 0 80 for 80%, 0 85 for 85%, 0 90 for 90%. 0 95 for 95%. 0 97 for 97% or 1 00 for 100%. and • is the symbol for the multiplication operator, and wherein any non-integer product of x n and y is rounded down to the nearest integer prior to subtracting it from x n Alterations of a polynucleotide sequence encoding the pohpeptide of SEQ ID NOS 2 or 4 may create nonsense, missense or frameshift mutations in this codmg sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations By way of example, a polynucleotide sequence of the present invention may be identical to the reference sequence of SEQ ID NOS 1 or 3, that is it may be 100% identical, or it may mclude up to a certain integer number of nucleic acid alterations as compared to the reference sequence such that the percent identity is less than 100% identity Such alterations are selected from the group consistmg of at least one nucleic acid deletion, substitution, including transition and transversion, or insertion, and wherem said alterations may occur at the 5 ' or 3' terminal positions of the reference polynucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleic acids in the reference sequence or in one or more contiguous groups within the reference sequence The number of nucleic acid alterations for a given percent identity is determined by multiplying the total number of nucleic acids m SEQ ID NOS 1 or 3 by the mteger defining the percent identity divided by 100 and then subtractmg that product from said total number of nucleic acids in SEQ ID NOS 1 or 3, or «n ≤ *n " ( x n • y)> wherem n n is the number of nucleic acid alterations, x n is the total number of nucleic acids m SEQ ID NOS 1 or 3, y is, for instance 0 70 for 70%, 0 80 for 80%, 0 85 for 85% etc . • is the symbol for the multiplication operator, and wherem any non-mteger product of x n and y is rounded down to the nearest integer prior to subtractmg it from x n (2) Polypeptide embodiments further include an isolated polypeptide comprising a pohpeptide having at least a 50.60. 70, 80. 85. 90. 95. 97 or 100% identity to a polypeptide reference sequence of SEQ ID NOS 2 or 4, wherem said polypeptide sequence may be identical to the reference sequence of SEQ ID NOS 2 or 4 or may mclude up to a certain mteger number of ammo acid alterations as compared to the reference sequence, wherem said alterations are selected from the group consisting of at least one ammo acid deletion, substitution, mcludmg conservative and non-conservative substitution, or insertion, and wherem said alterations may occur at the ammo- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the ammo acids in the reference sequence or m one or more contiguous groups within the reference sequence, and wherem said number of amino acid alterations is determined by multiplymg the total number of ammo acids in SEQ ID NOS 2 or 4 by the mteger defining the percent identity divided by 100 and then subtractmg that product from said total number of ammo acids in SEQ ID NOS 2 or 4. or n a < x a - (x a • y), wherem n a is the number of amino acid alterations, x a is the total number of ammo acids m SEQ ID NOS 2 or 4, y is 0 50 for 50%, 0 60 for 60%. 0 70 for 70%, 0 80 for 80%. 0 85 for 85%, 0 90 for 90%, 0 95 for 95%, 0 97 for 97% or 1 00 for 100%, and • is the symbol for the multiplication operator, and wherem any non-mteger product of x a and y is rounded down to the nearest mteger pπor to subtractmg it from x a By way of example, a polypeptide sequence of the present mvention may be identical to the reference sequence of SEQ ID NOS 2 or 4. that is it may be 100% identical, or it may mclude up to a certain mteger number of ammo acid alterations as compared to the reference sequence such that the percent identity is less than 100% identity Such alterations are selected from the group consistmg of at least one ammo acid deletion, substitution, mcludmg conservative and non- conservative substitution, or insertion, and wherem said alterations may occur at the ammo- or carboxy-termmal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the ammo acids m the reference sequence or m one or more contiguous groups within the reference sequence The number of amino acid alterations for a given % identity is determmed by multiplying the total number of amino acids m SEQ ID NOS 2 or 4 by the integer defining the percent identity divided by 100 and then subtractmg that product from said total number of ammo acids m SEQ ID NOS 2 or 4, or n a < x a - (x a • y), wherem n a is the number of ammo acid alterations. x a is the total number of ammo acids in SEQ ID NOS 2 or 4, y is, for instance 0 70 for 70%. 0 80 for 80%, 0 85 for 85% etc , and • is the symbol for the multiplication operator, and wherein any non-integer product of x a and y is rounded down to the nearest integer pπor to subtracting it from x a "Isolated" means altered "by the hand of man" from its natural state, i e , if it occurs in nature, it has been changed or removed from its original environment, or both For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein "Polynucleotide(s)" generally refers to any polyπbonucleotide or polydeoxπbonucleotide, which ma}' be unmodified RNA or DNA or modified RNA or DNA "Polynucleotide(s)" mclude, without limitation, smgle- and double-stranded DNA. DNA that is a mixture of smgle- and double- stranded regions or smgle-, double- and triple-stranded regions, smgle- and double-stranded RNA, and RNA that is mixture of smgle- and double-stranded regions, hybnd molecules compπsmg DNA and RNA that may be single-stranded or, more typically, double-stranded, or triple-stranded regions, or a mixture of smgle- and double-stranded regions In addition, "polynucleotide" as used herem refers to tπple-stranded regions compπsmg RNA or DNA or both RNA and DNA The strands m such regions may be from the same molecule or from different molecules The regions may mclude all of one or more of the molecules, but more typically mvolve only a region of some of the molecules One of the molecules of a tπple-hehcal region often is an oligonucleotide As used herein, the term "polynucleotide(s)" also mcludes DNAs or RNAs as descnbed above that contain one or more modified bases Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotιde(s)" as that term is intended herein Moreover, DNAs or RNAs compπsmg unusual bases, such as inosine. or modified bases, such as tntylated bases, to name just two examples, are polynucleotides as the term is used herem It will be appreciated that a great vaπety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art The term "polynucleotιde(s)" as it is employed herem embraces such chemically, enzymatically or metabohcally modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteπstic of viruses and cells, mcludmg for example, simple and complex cells "Polynucleotide(s)" also embraces short polynucleotides often refeπed to as olιgonucleotide(s) "Polypeptιde(s)" refers to any peptide or protein compπsmg two or more amino acids joined to each other by peptide bonds or modified peptide bonds "Polypeptide(s)" refers to both short chains, commonly refeπed to as peptides, o gopeptides and ohgomers and to longer chains generally refeπed to as proteins Polypeptides may contain ammo acids other than the 20 gene encoded ammo acids "Polypeptιde(s)" mclude those modified either by natural processes, such as processmg and other post-translational modifications, but also by chemical modification techniques Such modifications are well descnbed m basic texts and m more detailed monographs, as well as in a voluminous research literature, and they are well known to those of skill m the art It will be appreciated that the same type of modification may be present in the same or varying degree at several sites m a given polypeptide Also, a given polypeptide may contain many types of modifications Modifications can occur anywhere in a polypeptide. mcludmg the peptide backbone, the ammo acid side-chains, and the ammo or carboxyl termini Modifications mclude, for example, acetylation. acylation, ADP-nbosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide denvative, covalent attachment of a pid or kpid denvative. covalent attachment of phosphotidyhnositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, lodination, methylation, mynstoylation, oxidation, proteolytic processmg. phosphorylation prenylation, racemrzation. glycosylation, pid attachment, sulfation. gamma- carboxylation of glutamic acid residues, hydroxylation and ADP-πbosylation. selenoylation. sulfation. transfer-RNA mediated addition of ammo acids to proteins, such as arginylation, and ubiquitination See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES. 2nd Ed , T E Creighton, W H Freeman and Company, New York (1993) and Wold, F . Posttranslational Protein Modifications Perspectives and Prospects, pgs 1-12 m POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B C Johnson, Ed . Academic Press. New York (1983), Seifter et al , Meth Enzymol 182 626-646 (1990) and Rattan et al . Protein Synthesis Posttranslational Modifications and Aging, Ann N Y Acad Sci 663 48- 62 (1992) Polypeptides may be branched or cyclic with or without branching Cyclic, branched and branched circular polypeptides may result from post-translational natural processes and may be made by entirely synthetic methods, as well 'Naπant(s) ' as the term is used herem. is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide Changes m the nucleotide sequence of the variant may or may not alter the ammo acid sequence of a polypeptide encoded by the reference polynucleotide Nucleotide changes may result in ammo acid substitutions, additions, deletions, fusions and truncations m the polypeptide encoded by the reference sequence, as discussed below A typical vaπant of a polypeptide differs m ammo acid sequence from another, reference polypeptide Generally differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, m many regions, identical A variant and reference polypeptide may differ m ammo acid sequence by one or more substitutions, additions, deletions m any combmation A substituted or inserted ammo acid residue may or may not be one encoded by the genetic code A variant of a polynucleotide or polypeptide may be a naturally occurring such as an alle c vanant, or it may be a variant that is not known to occur naturally Non- naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques, by direct synthesis, and by other recombinant methods known to skilled artisans DESCRIPTION OF THE INVENTION The invention relates to clpL polypeptides and polynucleotides as described in greater detail below. In particular, the invention relates to polypeptides and polynucleotides of a clpL of Staphylococcus aureus, which is related by amino acid sequence homology to Lactococcus lactis clpL polypeptide. The invention relates especially to clpL having the nucleotide and amino acid sequences set out in Table 1 [SEQ ID NO: 1] and Table 1 [SEQ ID NO: 2] respectively, and to the clpL nucleotide sequences of the DNA in the deposited strain and amino acid sequences encoded thereby. TABLE 1 clpL Polynucleotide and Polypeptide Sequences (A) Sequences from Staphylococcus aureus clpL polynucleotide sequence [SEQ ID NO:l]. 5 '-1 TATATAGTTT GCATAACGCT TCAAAAGTAA TTTCTTTTTT GTTTAGTTCA 51 AAAAAATTTA GAGGTGATGT TATATGAATA ACGGTTTTTT CAATAGCGAC 101 TTTGATTCAA TTTTTCGAAG AATGATGCAA GATATGCAAG GTTCAAATCA 151 AGTCGGTAAC AAAAAGTACT ATATTAATGG TAAAGAAGTT TCACCTGAAG 201 AACTAGCGCA ACTCACACAA CAAGGTAGCA ATCAATCTGC TGAACAAAGT 251 GCGCAAGCTT TTCAACAAGC AGCACAAAGA CAACAAGGGC AACAAGGTGG 301 CAACGGCAAT TATTTAGAAC AAATTGGTCG TAACCTTACG CAAGAAGCAC 351 GTGACGGTTT ATTAGATCCA GTCATTGGTC GTGATAAAGA AATTCAAGAA 401 ACTGCTGAAG TCTTAAGTAG ACGAACTAAA AACAATCCCT ATATTAGTTG 451 GAGAGCTGGT GTGGTAT-3' (B) clpL polypeptide sequence deduced from the polynucleotide sequence in this table translation starts at nucleotide 74 [SEQ ID NO:2]. NH 2 -1 MNNGFFNSDF DSIFRRMMQD MQGSNQVGNK KYYINGKEVS PEELAQLTQQ 51 GSNQSAEQSA QAFQQAAQRQ QGQQGGNGNY LEQI GRNLTQ EARDGLLDPV 101 I GRDKEIQET AEVLSRRTKN NPYI S RAGV V-COOH (C) Polynucleotide sequence embodiments [SEQ ID NO: 1]. X-(R 1 ) n -l TATATAGTTT GCATAACGCT TCAAAAGTAA TTTCTTTTTT GTTTAGTTCA 51 AAAAAATTTA GAGGTGATGT TATATGAATA ACGGTTTTTT CAATAGCGAC 101 TTTGATTCAA TTTTTCGAAG AATGATGCAA GATATGCAAG GTTCAAATCA 151 AGTCGGTAAC AAAAAGTACT ATATTAATGG TAAAGAAGTT TCACCTGAAG 201 AACTAGCGCA ACTCACACAA CAAGGTAGCA ATCAATCTGC TGAACAAAGT 251 GCGCAAGCTT TTCAACAAGC AGCACAAAGA CAACAAGGGC AACAAGGTGG 301 CAACGGCAAT TATTTAGAAC AAATTGGTCG TAACCTTACG CAAGAAGCAC 351 GTGACGGTTT ATTAGATCCA GTCATTGGTC GTGATAAAGA AATTCAAGAA 401 ACTGCTGAAG TCTTAAGTAG ACGAACTAAA AACAATCCCT ATATTAGTTG 451 GAGAGCTGGT GTGGTAT- ( R 2 ) n ~Y (D) Polypeptide sequence embodiments [SEQ ID NO 2] χ A R l)n -1 MNNGFFNSDF DSIFRRMMQD MQGSNQVGNK KYYINGKEVS PEE AQLTQQ 51 GSNQSAEQSA QAFQQAAQRQ QGQQGGNGNY LEQIGRNLTQ EARDGLLDPV 101 IGRDKEIQET AEVLSRRTKN NPYISWRAGV V-(R 2 ) n -Y Deposited materials A deposit containing a Staphylococcus aureus WCUH 29 stram has been deposited with the National Collections of Industnal and Marme Bactena Ltd (herem "NCIMB"), 23 St Machar Dnve, Aberdeen AB2 1RY, Scotland on 11 September 1995 and assigned NCIMB Deposit No 40771 The Staphylococcus aureus stram deposit is refened to herem as "the deposited stram" or as "the DNA of the deposited stram " The deposited stram contains the full length clpL gene The sequence of the polynucleotides contamed m the deposited strain, as well as the ammo acid sequence of the polypeptide encoded thereby, are controlling m the event of any conflict with any descnption of sequences herem The deposit of the deposited stram has been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure The stram will be πrevocably and without restnction or condition released to the public upon the issuance of a patent The deposited stram is provided merely as convemence to those of skill in the art and is not an admission that a deposit is required for enablement, such as that required under 35 U S C §112 A license may be required to make, use or sell the deposited stram, and compounds denved therefrom, and no such license is hereby granted Polypeptides The polypeptides of the mvention mclude the polypeptide of Table 1 [SEQ ID NO 2] (m particular the mature polypeptide) as well as polypeptides and fragments, particularly those which have the biological activity of clpL, and also those which have at least 70% identity to the polypeptide of Table 1 [SEQ ID NO 2] or the relevant portion, preferably at least 80% identity to the polypeptide of Table 1 [SEQ ID NO 2]. and more preferably at least 90% similaπty (more preferably at least 90% identity) to the polypeptide of Table 1 [SEQ ID NO 2] and still more preferably at least 95% similanty (still more preferably at least 95% identity) to the polypeptide of Table 1 [SEQ ID NO 2] and also mclude portions of such polypeptides with such portion of the polypeptide generally containing at least 30 ammo acids and more preferably at least 50 ammo acids The mvention also mcludes polypeptides of the formula set forth m Table 1 (D) wherein, at the ammo termmus, X is hydrogen, and at the carboxyl termmus. Y is hydrogen or a metal, Ri and R2 is any ammo acid residue, and n is an mteger between 1 and 1000 Any stretch of ammo acid residues denoted by either R group, where R is greater than 1, may be either a heteropolymer or a homopolymer. preferably a heteropolymer A fragment is a vanant polypeptide having an ammo acid sequence that entirely is the same as part but not all of the ammo acid sequence of the aforementioned polypeptides As with clpL polypeptides fragments may be "free-standmg," or compnsed within a larger polypeptide of which they form a part or region, most preferably as a smgle continuous region, a smgle larger polypeptide Prefened fragments mclude. for example, truncation polypeptides having a portion of the ammo acid sequence of Table 1 [SEQ ID NO 2]. or of vaπants thereof, such as a contmuous seπes of residues that mcludes the ammo termmus, or a contmuous senes of residues that mcludes the carboxyl termmus Degradation forms of the polypeptides of the mvention m a host cell, particularly a Staphylococcus aureus, are also prefened Further prefened are fragments characterized by structural or functional attributes such as fragments that compnse alpha-hehx and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-formmg regions, substrate b dmg region, and high antigenic index regions Also prefened are biologically active fragments which are those fragments that mediate activities of clpL. mcludmg those with a similar activity or an improved activity, or with a decreased undesirable activity Also mcluded are those fragments that are antigenic or lmmunogenic m an animal, especially m a human Particularly prefened are fragments compnsmg receptors or domains of enzymes that confer a function essential for viability of Staphylococcus aureus or the ability to initiate, or maintain cause disease m an individual, particularly a human Vaπants that are fragments of the polypeptides of the mvention may be employed for producmg the coπesponding full-length polypeptide by peptide synthesis, therefore, these vaπants may be employed as intermediates for producmg the full-length polypeptides of the mvention Polynucleotides Another aspect of the mvention relates to isolated polynucleotides that encode the clpL polypeptide having the deduced ammo acid sequence of Table 1 [SEQ ID NO 2] and polynucleotides closely related thereto and vanants thereof Using the information provided herein, such as the polynucleotide sequence set out m Table 1 [SEQ ID NO 1], a polynucleotide of the mvention encoding clpL polypeptide may be obtained usmg standard cloning and screening methods, such as those for cloning and sequencmg chromosomal DNA fragments from bactena usmg Staphylococcus aureus WCUH 29 cells as starting matenal, followed by obtaining a full length clone For example, to obtain a polynucleotide sequence of the invention, such as the sequence given in Table 1 [SEQ ID NO 1]. typically a library of clones of chromosomal DNA of Staphylococcus aureus WCUH 29 m E coll or some other suitable host is probed with a radiolabeled oligonucleotide. preferably a 17-mer or longer, derived from a partial sequence Clones carrying DNA identical to that of the probe can then be distinguished using strmgent conditions By sequencmg the individual clones thus identified with sequencing primers designed from the original sequence it is then possible to extend the sequence m both directions to determine the full gene sequence Conveniently, such sequencmg is performed usmg denatured double stranded DNA prepared from a plasmid clone Suitable techniques are described by Maniatis, T . Fπtsch, E F and Sambrook et al . MOLECULAR CLONING A LABORATORY MANUAL, 2nd Ed , Cold Sprmg Harbor Laboratory Press. Cold Sprmg Harbor, New York (1989) (see m particular Screemng By Hybπdization 1 90 and Sequencing Denatured Double-Stranded DNA Templates 13 70) Illustrative of the mvention, the polynucleotide set out in Table 1 [SEQ ID NO 1] was discovered m a DNA library denved from Staphylococcus aureus WCUH 29 The DNA sequence set out in Table 1 [ SEQ ID NO 1] contains an open reading frame encoding a protem having about or exactly the number of ammo acid residues set forth m Table 1 [SEQ ID NO 2] with a deduced molecular weight that can be calculated usmg ammo acid residue molecular weight values well known m the art The open reading frame may be coπelated with the polypeptide of Table 1 [SEQ ID NO 2] by usmg a codon chart well known m the art or any algonthm for detectmg open reading frames, such as the known methods of Framesearch (Wisconsin Package of the Genetics Computer Group (GCG) software), TBLASTN (Blast software from NCBI), and FASTA (TFASTX of Pearson & Lipman, PNAS 85 2444 (1988) The clpL polypeptide of the mvention is structurally related to other proteins of the Clp ATPases family, as shown by the results of sequencmg the DNA encoding clpL of the deposited stram The protem exhibits greatest homology to Lactococcus lactis clpL protem among known proteins The clpL polypeptide of Table 1 [SEQ ED NO 2] has about 32% identity over its entire length and about 52% similaπty over its entire length with the ammo acid sequence of Lactococcus lactis clpL polypeptide The mvention provides a polynucleotide sequence identical over its entire length to the codmg sequence m Table 1 [SEQ ID NO 1] Also provided by the mvention is the codmg sequence for the mature polypeptide or a fragment thereof, by itself as well as the codmg sequence for the mature polypeptide or a fragment in readmg frame with other codmg sequence, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protem sequence The polynucleotide ma's also contain non-coding sequences mcludmg for example but not limited to non-coding 5 and 3' sequences, such as the transcπbed. non-translated sequences, termination signals, nbosome bmdmg sites, sequences that stabilize mRNA. introns, polyadenylation signals, and additional codmg sequence which encode additional ammo acids For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded In certain embodiments of the mvention. the marker sequence is a hexa-histidine peptide, as provided m the pQE vector (Qiagen. Inc ) and descnbed m Gentz et al , Proc Natl Acad Su USA 86 821-824 (1989). or an HA tag (Wilson et al , Cell 37 767 (1984) Polynucleotides of the mvention also mclude but are not limited to, polynucleotides compπsmg a structural gene and its naturally associated sequences that control gene expression A prefened embodiment of the mvention is the polynucleotide compnsing nucleotide set forth m SEQ ID NO 1 of Table 1 which encodes the clpL polypeptide The mvention also mcludes polynucleotides of the formula set forth in Table 1 (C) wherem, at the 5' end of the molecule. X is hydrogen, and at the 3' end of the molecule, Y is hydrogen or a metal, Ri and R2 is any nucleic acid residue, and n is an mteger between 1 and 1000 Any stretch of nucleic acid residues denoted by either R group, where R is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer The term "polynucleotide encoding a polypeptide" as used herem encompasses polynucleotides that mclude a sequence encoding a polypeptide of the mvention, particularly a bactenal polypeptide and more particularly a polypeptide of the Staphylococcus aureus clpL having the ammo acid sequence set out m Table 1 [SEQ ID NO 2] The term also encompasses polynucleotides that mclude a smgle contmuous region or discontinuous regions encoding the polypeptide (for example, interrupted by integrated phage or an insertion sequence or editing) together with additional regions, that also may contain codmg and/or non-coding sequences The mvention further relates to vaπants of the polynucleotides descnbed herem that encode for vanants of the polypeptide having the deduced ammo acid sequence of Table 1 [SEQ ED NO 2] Vanants that are fragments of the polynucleotides of the mvention may be used to synthesize full- length polynucleotides of the mvention Further particularly prefened embodiments are polynucleotides encoding clpL vaπants. that have the am o acid sequence of clpL polypeptide of Table 1 [SEQ ID NO 2] m which several, a few, 5 to 10 1 to 5, 1 to 3. 2. 1 or no ammo acid residues are substituted, deleted or added, m am combmation Especially prefened among these are silent substitutions additions and deletions, that do not alter the properties and activities of clpL Further prefened embodiments of the mvention are polynucleotides that are at least 70% identical over their entire length to a polynucleotide encoding clpL polypeptide having the ammo acid sequence set out in Table 1 [SEQ ID NO 2], and polynucleotides that are complementary to such polynucleotides Alternatively, most highly prefened are polynucleotides that compnse a region that is at least 80% identical over its entire length to a polynucleotide encoding clpL polypeptide of the deposited stram and polynucleotides complementary thereto In this regard, polynucleotides at least 90% identical over their entire length to the same are particularly prefened, and among these particularly prefened polynucleotides. those with at least 95% are especially prefened Furthermore, those with at least 97% are highly prefened among those with at least 95%. and among these those with at least 98% and at least 99% are particularly highly prefened, with at least 99% bemg the more prefened Prefened embodiments are polynucleotides that encode polypeptides that retain substantially the same biological function or activity as the mature polypeptide encoded by the DNA of Table 1 [SEQ ID NO 1] The mvention further relates to polynucleotides that hybndize to the herem above-descπbed sequences In this regard, the mvention especially relates to polynucleotides that hybndize under stringent conditions to the herem above-descπbed polynucleotides As herem used, the terms "stringent conditions" and "stringent hybndization conditions" mean hybπdization will occur only if there is at least 95% and preferably at least 97% identity between the sequences An example of strmgent hybridization conditions is overnight mcubation at 42°C m a solution compπsmg 50% formamide. 5x SSC (150mM NaCl, 15mM tnsodium citrate), 50 mM sodium phosphate (pH7 6). 5x Denhardt's solution, 10% dextran sulfate. and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing the hybridization support m 0 lx SSC at about 65 °C Hybndization and wash conditions are well known and exemplified m Sambrook. et al , Molecular Cloning A Laboratory Manual, Second Edition, Cold Sprmg Harbor. N Y . (1989), particularly Chapter 11 therem The mvention also provides a polynucleotide consisting essentially of a polynucleotide sequence obtamable by screening an appropriate library containing the complete gene for a polynucleotide sequence set forth in SEQ ID NO 1 under stringent hybπdization conditions with a probe having the sequence of said polynucleotide sequence set forth m SEQ ID NO 1 or a fragment thereof, and isolating said DNA sequence Fragments useful for obtaining such a polynucleotide mclude. for example, probes and primers described elsewhere herem As discussed additionally herem regarding polynucleotide assays of the mvention. for instance, polynucleotides of the mvention as discussed above, may be used as a hybπdization probe for RNA. cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encodmg clpL and to isolate cDNA and genomic clones of other genes that have a high sequence similaπty to the clpL gene Such probes generally will compnse at least 15 bases Preferably, such probes will have at least 30 bases and may have at least 50 bases Particularly prefened probes will have at least 30 bases and will have 50 bases or less For example, the codmg region of the clpL gene may be isolated by screemng usmg the DNA sequence provided m SEQ ID NO 1 to synthesize an oligonucleotide probe A labeled oligonucleotide having a sequence complementary to that of a gene of the mvention is then used to screen a library of cDNA, genomic DNA or mRNA to determine which members of the library the probe hybndizes to The polynucleotides and polypeptides of the mvention may be employed, for example, as research reagents and mateπals for discovery of treatments of and diagnostics for disease, particularly human disease, as further discussed herem relating to polynucleotide assays Polynucleotides of the invention that are ohgonucleotides derived from the sequences of SEQ ID NOS 1 and/or 2 may be used in the processes herem as described, but preferably for PCR, to determine whether or not the polynucleotides identified herem in whole or m part are transcnbed m bacteria in mfected tissue It is recognized that such sequences will also have utility in diagnosis of the stage of infection and type of mfection the pathogen has attained The invention also provides polynucleotides that may encode a polypeptide that is the mature protein plus additional amino or carboxyl-teπninal amino acids, or amino acids interior to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, may allow protein transport, may lengthen or shorten protein half-life or may facilitate manipulation of a protein for assay or production, among other things. As generally is the case in vivo, the additional amino acids may be processed away from the mature protein by cellular enzymes. A precursor protein, having the mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide. When prosequences are removed such inactive precursors generally are activated. Some or all of the prosequences may be removed before activation. Generally, such precursors are called proproteins. In sum, a polynucleotide of the invention may encode a mature protein, a mature protein plus a leader sequence (which may be refened to as a preprotein), a precursor of a mature protein having one or more prosequences that are not the leader sequences of a preprotein, or a preproprotein, which is a precursor to a proprotein, having a leader sequence and one or more prosequences, which generally are removed during processing steps that produce active and mature forms of the polypeptide. Vectors, host cells, expression The invention also relates to vectors that comprise a polynucleotide or polynucleotides of the invention, host cells that are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the invention. For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof or polynucleotides of the invention. Introduction of a polynucleotide into the host cell can be effected by methods described in many standard laboratory manuals, such as Davis et al, BASIC METHODS LN MOLECULAR BIOLOGY, (1986) and Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. (1989), such as, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid- mediated transfection, electroporation, transduction, scrape loading, ballistic introduction and infection. Representative examples of appropnate hosts mclude bacteπal cells, such as streptococci, staphylococci, enterococci E coh, streptomyces and Bacillus subtihs cells, fungal cells, such as yeast cells and Aspergillus cells, insect cells such as Drosophila S2 and Spodoptera Sf9 cells, animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293 and Bowes melanoma cells, and plant cells A great vaπety of expression systems can be used to produce the polypeptides of the mvention Such vectors mclude. among others, chromosomal, episomal and virus-denved vectors, e g , vectors denved from bactenal plasmids, from bactenophage, from transposons, from yeast episomes. from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova vuuses, such as SV40, vaccinia viruses, adenoviruses. fowl pox viruses, pseudorabies viruses and retroviruses, and vectors denved from combinations thereof, such as those denved from plasnud and bactenophage genetic elements, such as cosmids and phagemids The expression system constructs may contain control regions that regulate as well as engender expression Generally, any system or vector suitable to maintain, propagate or express polynucleotides and/or to express a polypeptide m a host may be used for expression m this regard The appropnate DNA sequence may be inserted mto the expression system by any of a vaπety of well-known and routine techniques, such as, for example, those set forth m Sambrook et al , MOLECULAR CLONING, A LABORATORY MANUAL, (supra) For secretion of the translated protem mto the lumen of the endoplasmic reticulum. mto the penplasmic space or mto the extracellular environment, appropnate secretion signals may be incorporated mto the expressed polypeptide These signals may be endogenous to the polypeptide or they may be heterologous signals Polypeptides of the mvention can be recovered and puπfied from recombinant cell cultures by well-known methods mcludmg ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic mteraction chromatography, affinity chromatography, hydroxylapatite chromatography, and lectm chromatography Most preferably, high performance liquid chromatography is employed for purification Well known techniques for refolding protem may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification Diagnostic Assays This mvention is also related to the use of the clpL polynucleotides of the mvention for use as diagnostic reagents Detection of clpL in a eukaryote, particularly a mammal, and especially a human, will provide a diagnostic method for diagnosis of a disease Eukaryotes (herem also "ιndιvιdual(s)"), particularly mammals, and especially humans, particularly those infected or suspected to be infected with an organism compπsmg the clpL gene may be detected at the nucleic acid level by a vaπety of techniques Nucleic acids for diagnosis may be obtained from an infected individual's cells and tissues, such as bone, blood, muscle, cartilage, and skin Genomic DNA may be used directly for detection or may be amplified enzymatically by usmg PCR or other amplification technique pπor to analysis RNA or cDNA may also be used m the same ways Usmg amplification, characterization of the species and stram of prokaryote present m an individual, may be made by an analysis of the genotype of the prokaryote gene Deletions and insertions can be detected by a change in size of the amplified product m compaπson to the genotype of a reference sequence Pomt mutations can be identified by hybndizing amplified DNA to labeled clpL polynucleotide sequences Perfecth matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures DNA sequence differences may also be detected by alterations in the electrophoretic mobility of the DNA fragments m gels, with or without denaturmg agents, or by direct DNA sequencmg See, e g , Myers et al . Science, 230 1242 (1985) Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase and SI protection or a chemical cleavage method See. e g . Cotton et al , Proc Natl Acad Sci , USA, 85 4397-4401 (1985) Cells carrying mutations or polymorphisms m the gene of the mvention may also be detected at the DNA level by a vanety of techniques, to allow for serotyping. for example For example. RT- PCR can be used to detect mutations It is particularly prefened to used RT-PCR in conjunction with automated detection systems, such as, for example, GeneScan RNA or cDNA may also be used for the same purpose, PCR or RT-PCR As an example, PCR primers complementary to a nucleic acid encoding clpL can be used to identify and analyze mutations The mvention further provides these primers with 1, 2. 3 or 4 nucleotides removed from the 5' and/or the 3' end These primers may be used for. among other things, amplifying clpL DNA isolated from a sample denved from an individual The primers may be used to amplify the gene isolated from an infected individual such that the gene may then be subject to vaπous techniques for elucidation of the DNA sequence In this way, mutations m the DNA sequence may be detected and used to diagnose infection and to serotype and/or classify the infectious agent The mvention further provides a process for diagnosing, disease, preferably bacteπal infections, more preferably infections by Staphylococcus aureus, and most preferably disease, such as, infections of the upper respiratory tract (e g , otitis media, bactenal tracheitis, acute epiglottitis, thyroiditis). lower respiratory (e g , empyema, lung abscess), cardiac (e g , infective endocarditis), gastrointestinal (e g . secretory dianhoea. splenic abscess, retropentoneal abscess), CNS (e g , cerebral abscess), eye (e g , blephaπtis. conjunctivitis, keratitis. endophthalmitis, preseptal and orbital cellulitis. darcryocystitis), kidney and urinary tract (e g , epididymitis, mtrarenal and peπnephnc abscess, toxic shock syndrome), skin (e g , impetigo, follicu tis. cutaneous abscesses, cellulitis. wound infection, bactenal myositis) bone and jomt (e g , septic arthntis. osteomyelitis), compπsmg determmmg from a sample derived from an individual a increased level of expression of polynucleotide having the sequence of Table 1 [SEQ ID NO 1] Increased or decreased expression of clpL polynucleotide can be measured using any on of the methods well known m the art for the quantation of polynucleotides, such as. for example, amplification, PCR, RT-PCR. RNase protection. Northern blotting and other hybridization methods In addition, a diagnostic assay m accordance with the mvention for detecting over- expression of clpL protem compared to normal control tissue samples may be used to detect the presence of an infection, for example Assay techniques that can be used to determine levels of a clpL protem. m a sample denved from a host are well-known to those of skill m the art Such assay methods mclude radioimmunoassays. competitive-binding assays, Western Blot analysis and ELISA assays Antibodies The pohpeptides of the mvention or vanants thereof, or cells expressmg them can be used as an lmmunogen to produce antibodies unmunospecific for such polypeptides "Antibodies" as used herem mcludes monoclonal and polyclonal antibodies, chimenc, smgle chain, simianized antibodies and humanized antibodies, as well as Fab fragments, mcludmg the products of an Fab lmmunolglobuhn expression library Antibodies generated against the polypeptides of the mvention can be obtained by administering the polypeptides or epitope-beanng fragments, analogues or cells to an animal, preferably a nonhuman. usmg routine protocols For preparation of monoclonal antibodies, any techmque known m the art that provides antibodies produced by continuous cell lme cultures can be used Examples mclude vanous techniques, such as those m Kohler, G and Milstein, C , Nature 256 495-497 (1975). Kozbor et al , Immunology Today 4 72 (1983). Cole et al , pg 77-96 in MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R Liss, Inc (1985) Techniques for the production of smgle cham antibodies (U S Patent No 4,946,778) can be adapted to produce smgle cham antibodies to polypeptides of this mvention Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies Alternatively phage display technology may be utilized to select antibody genes with bmdmg activities towards the polypeptide either from repertoires of PCR amplified v-genes of lymphocytes from humans screened for possessmg anti-clpL or from naive hbranes (McCafferty. J et al , (1990), Nature 348, 552-554, Marks, J et al , (1992) Biotechnology 10, 779-783) The affinity of these antibodies can also be improved by cham shufϊlmg (Clackson, T et al (1991) Nature 352 624-628) If two antigen binding domains are present each domain may be directed agamst a different epitope - termed 'bispecific' antibodies The above-descnbed antibodies may be employed to isolate or to identify' clones expressmg the polypeptides to punfy the polypeptides by affinity chromatography Thus, among others, antibodies agamst clpL- polypeptide may be employed to treat infections, particularly bactenal infections and especially disease, such as, infections of the upper respiratory tract (e g , otitis media, bactenal tracheitis. acute epiglottitis. thyroiditis). lower respiratory (e g , empyema, lung abscess), cardiac (e g , infective endocarditis), gastrointestinal (e g , secretory dianhoea. splemc abscess, retropentoneal abscess). CNS (e g , cerebral abscess), eye (e g , blephaπtis. conjunctivitis, keratitis, endophthalmitis, preseptal and orbital cellulitis. darcryocvstitis), kidney and urinary tract (e g , epididymitis, mtrarenal and peπnephπc abscess, toxic shock syndrome) skin (e g , impetigo, follicuhtis, cutaneous abscesses, cellulitis, wound infection, bactenal myositis) bone and joint (e g , septic arthπtis, osteomyelitis) Polypeptide variants mclude antigemcally, epitopically or immunologically equivalent vaπants that form a particular aspect of this invention The term "antigemcally equivalent derivative" as used herem encompasses a polypeptide or its equivalent which will be specificalh recognized by certain antibodies which, when raised to the protem or polypeptide according to the mvention, interfere with the immediate physical mteraction between pathogen and mammahan host The term "immunologically equivalent denvative" as used herem encompasses a peptide or its equivalent which when used m a suitable formulation to raise antibodies in a vertebrate, the antibodies act to interfere with the immediate physical mteraction between pathogen and mammalian host The polypeptide. such as an antigemcally or immunologically equivalent deπvatπ e or a fusion protem thereof is used as an antigen to immunize a mouse or other animal such as a rat or chicken The fusion protem may provide stability to the polypeptide The antigen may be associated, for example by conjugation, with an lmmunogenic carrier protein for example bovme serum albumin (BSA) or keyhole limpet haemocyanm (KLH) Alternatively a multiple antigenic peptide compnsmg multiple copies of the protem or polypeptide. or an antigemcally or immunologically equivalent polypeptide thereof may be sufficiently antigenic to improve lmmunogenicity so as to obviate the use of a carrier Preferably . the antibody or vaπant thereof is modified to make it less lmmunogenic in the individual For example, if the individual is human the antibody may most preferably be "humanized", where the comp mentaπty determining regιon(s) of the hybπdoma-deπved antibody has been transplanted mto a human monoclonal antibody , for example as descnbed in Jones, P et al (1986), Nature 321, 522-525 or Tempest et al .(1991) Biotechnology 9, 266- 273 The use of a polynucleotide of the invention in genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA mto muscles (Wolff et al . Hum Mol Genet 1992. 1 363, Manthorpe et al . Hum Gene Ther 1963 4, 419). delivery of DNA complexed with specific protem earners (Wu et al , J Biol Chem 1989 264, 16985). coprecipitation of DNA with calcium phosphate (Benvemsty & Reshef, PNAS USA. 1986 83,9551). encapsulation of DNA m various forms of hposomes (Kaneda et al , Science 1989 243.375), particle bombardment (Tang et al , Nature 1992, 356 152, Eisenbraun et al , DNA Cell Biol 1993, 12 791) and in vivo mfection usmg cloned retroviral vectors (Seeger et al , PNAS USA 1984 81,5849) Antagonists and agonists - assays and molecules Polypeptides of the mvention may also be used to assess the bmdmg of small molecule substrates and hgands in, for example, cells, cell-free preparations, chemical hbranes, and natural product mixtures These substrates and hgands may be natural substrates and hgands or may be structural or functional mimetics See, e g , Coligan et al , Current Protocols in Immunology 1(2) Chapter 5 (1991) The mvention also provides a method of screemng compounds to identify those which enhance (agonist) or block (antagonist) the action of clpL polypeptides or polynucleotides, particularly those compounds that are bactenostatic and/or bacteπocidal The method of screemng may mvolve high-throughput techniques For example, to screen for agonists or antagoists, a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, compnsmg clpL polypeptide and a labeled substrate or ligand of such polypeptide is mcubated in the absence or the presence of a candidate molecule that may be a clpL agonist or antagonist The ability of the candidate molecule to agonize or antagonize the clpL polypeptide is reflected m decreased bmdmg of the labeled ligand or decreased production of product from such substrate Molecules that b d gratuitously, i e . without mducmg the effects of clpL polypeptide are most likely to be good antagomsts Molecules that bmd well and mcrease the rate of product production from substrate are agonists Detection of the rate or level of production of product from substrate may be enhanced by usmg a reporter system Reporter systems that may be useful m this regard mclude but are not limited to colonmetnc labeled substrate converted mto product, a reporter gene that is responsive to changes m clpL polynucleotide or polypeptide activity, and bmdmg assays known in the art Another example of an assay for clpL antagomsts is a competitive assay that combmes clpL and a potential antagonist with clpL-bmdmg molecules, recombinant clpL bmdmg molecules, natural substrates or hgands, or substrate or ligand mimetics, under appropnate conditions for a competitive inhibition assay The clpL molecule can be labeled, such as by radioactivity or a colonmetnc compound such that the number of clpL molecules bound to a bmdmg molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist Potential antagomsts mclude small orgamc molecules, peptides, polypeptides and antibodies that bmd to a polynucleotide or polypeptide of the mvention and thereby inhibit or extinguish its activity Potential antagomsts also may be small orgamc molecules, a peptide, a polypeptide such as a closely related protem or antibody that bmds the same sites on a bmdmg molecule, such as a bmdmg molecule, without mducmg clpL-mduced activities, thereby preventmg the action of clpL by excluding clpL from bmdmg Potential antagomsts mclude a small molecule that bmds to and occupies the bmdmg site of the polypeptide thereby preventmg bmdmg to cellular bmdmg molecules, such that normal biological activity is prevented Examples of small molecules mclude but are not limited to small organic molecules, peptides or peptide- ke molecules Other potential antagomsts mclude antisense molecules (see Okano. J Neurochem 56 560 (1991), OUGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION, CRC Press, Boca Raton. FL (1988). for a descπption of these molecules) Prefened potential antagomsts mclude compounds related to and vaπants of clpL Each of the DNA sequences provided herem may be used m the discovery and development of antibacterial compounds The encoded protem, upon expression, can be used as a target for the screemng of antibacteπal drugs Additionally, the DNA sequences encodmg the ammo terminal regions of the encoded protem or Shme-Delgarno or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of interest The mvention also provides the use of the polypeptide. polynucleotide or inhibitor of the invention to interfere with the initial physical mteraction between a pathogen and mammahan host responsible for sequelae of infection In particular the molecules of the invention may be used in the prevention of adhesion of bacteria, in particular gram positive bacteria, to mammalian extracellular matrix proteins on in-dwelling devices or to extracellular matrix proteins m ounds, to block clpL protem-mediated mammahan cell invasion by. for example, initiating phosphorylation of mammahan tyrosine kmases (Rosenshine et al . Infect Immun 60 2211 (1992). to block bacterial adhesion between mammahan extracellular matrix proteins and bactenal clpL proteins that mediate tissue damage and, to block the normal progression of pathogenesis in infections mitiated other than by the implantation of m-dwellmg devices or by other surgical techniques The antagomsts and agonists of the mvention may be employed, for instance, to inhibit and treat disease, such as. infections of the upper respiratory tract (e g , otitis media, bactenal tracheitis. acute epiglottitis, thyτoιdιtis), lower respiratory (e g . empyema, lung abscess), cardiac (e g , infective endocarditis), gastromtestmal (e g , secretory dianhoea, splemc abscess, retropentoneal abscess), CNS (e g . cerebral abscess), eye (e g . blephantis, conjunctivitis, keratitis, endophthalmitis. preseptal and orbital cellulitis, darcryocystitis), kidney and urinary tract (e g . epididymitis, mtrarenal and pennephπc abscess, toxic shock syndrome), skin (e g , impetigo, fol culitis, cutaneous abscesses, cellulitis. wound infection, bactenal myositis) bone and joint (e g , septic arthπtis, osteomyelitis) Hehcobacter pylori (herem H pylori) bactena mfect the stomachs of over one-third of the world's population causing stomach cancer, ulcers, and gastritis (International Agency for Research on Cancer (1994) Schistosomes, Liver Flukes and Hehcobacter Pylon (International Agency for Research on Cancer, Lyon, France, http //www uicc ch ecp/ecp2904 htm) Moreover, the international Agency for Research on Cancer recently recognized a cause-and- effect relationship between H pylori and gastπc adenocarcmoma, classifying the bacteπum as a Group I (definite) carcinogen Preferred antimicrobial compounds of the mvention (agonists and antagomsts of clpL) found using screens provided by the mvention. particularly broad- spectrum antibiotics, should be useful in the treatment of H pylori infection Such treatment should decrease the advent of H pylon-mά cQd cancers, such as gastromtestmal carcmoma Such treatment should also cure gastric ulcers and gastntis Vaccines Another aspect of the mvention relates to a method for mducmg an immunological response m an individual particularly a mammal which comprises inoculating the individual with clpL. or a fragment or variant thereof, adequate to produce antibody and/ or T cell immune response to protect said individual from infection, particularly bactenal infection and most particularly Staphylococcus aureus infection Also provided are methods whereby such immunological response slows bacterial replication Yet another aspect of the mvention relates to a method of inducing immunological response m an individual which comprises delivering to such individual a nucleic acid vector to direct expression of clpL, or a fragment or a vanant thereof, for expressing clpL, or a fragment or a variant thereof n vivo in order to mduce an immunological response, such as, to produce antibody and/ or T cell immune response, mcludmg. for example, cytokine-producing T cells or cytotoxic T cells, to protect said individual from disease, whether that disease is already established withm the individual or not One way of administering the gene is by acceleratmg it into the desired cells as a coatmg on particles or otherwise Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA RNA hybnd A further aspect of the invention relates to an immunological composition which, when mtroduced mto an individual capable or having induced within it an immunological response, induces an immunological response m such individual to a clpL or protem coded therefrom, wherem the composition compnses a recombmant clpL or protem coded therefrom compnsing DNA which codes for and expresses an antigen of said clpL or protem coded therefrom The immunological response may be used therapeutically or prophylactically and may take the form of antibody immunity or cellular immunity such as that arising from CTL or CD4+ T cells A clpL polypeptide or a fragment thereof may be fused with co-protem which may not by itself produce antibodies, but is capable of stabilizing the first protem and producmg a fused protem which will have lmmunogenic and protective properties Thus fused recombmant protein preferably further comprises an antigenic co-protem. such as lipoprotern D from Hemophύus influenzae, Glutathione-S-transferase (GST) or beta-galactosidase, relatively large co-proteins which solubihze the protem and facilitate production and purification thereof Moreoyer. the co-protein may act as an adjuvant in the sense of providmg a generalized stimulation of the immune system The co-protein may be attached to either the ammo or carbox\ termmus of the first protem Provided by this invention are compositions, particularly vaccine compositions, and methods compπsmg the polypeptides or polynucleotides of the invention and immunostimulatory DNA sequences, such as those described in Sato, Y et al Science 273 352 (1996) Also, provided by this mvention are methods using the descnbed polynucleotide or particular fragments thereof which have been shown to encode non-variable regions of bacterial cell surface protems m DNA constructs used m such genetic immunization experiments m animal models of mfection with Staphylococcus aureus will be particularly useful for identifymg protem epitopes able to provoke a prophylactic or therapeutic immune response It is believed that this approach will allow for the subsequent preparation of monoclonal antibodies of particular value from the requisite organ of the animal successfully resistmg or cleaπng infection for the development of prophylactic agents or therapeutic treatments of bacterial infection, particularly Staphylococcus aureus mfection, in mammals, particularly humans The polypeptide may be used as an antigen for vaccination of a host to produce specific antibodies which protect agamst invasion of bacteria, for example by blocking adherence of bactena to damaged tissue Examples of tissue damage mclude wounds m skin or connective tissue caused, e g . by mechanical, chemical or thermal damage or by implantation of mdwellmg devices, or wounds m the mucous membranes, such as the mouth, mammary glands, urethra or vagma The mvention also mcludes a vaccine formulation which comprises an lmmunogenic recombinant protem of the invention together with a suitable carrier Since the protem may be broken down in the stomach, it is preferably administered parenterally, mcludmg, for example, admimstration that is subcutaneous, intramuscular, intravenous, or mtradermal Formulations suitable for parenteral admimstration mclude aqueous and non-aqueous sterile mjection solutions which may contain anti-oxidants, buffers, bacteπostats and solutes which render the formulation msotonic with the bodily fluid, preferably the blood, of the individual, and aqueous and non-aqueous sterile suspensions which may mclude suspendmg agents or thickening agents The formulations may be presented m unit-dose or multi-dose contamers, for example, sealed ampules and vials and may be stored in a freeze-dπed condition requirmg only the addition of the sterile liquid carrier immediately prior to use The vaccine formulation may also mclude adjuvant systems for enhancing the lmmunogemcity of the formulation, such as oil-in water systems and other systems known in the art The dosage will depend on the specific activity of the vaccme and can be readily determmed by routine experimentation While the invention has been described with reference to certain clpL protem, it is to be understood that this covers fragments of the naturally occurring protem and similar protems with additions, deletions or substitutions which do not substantially affect the lmmunogenic properties of the recombinant protem Compositions, kits and administration The mvention also relates to compositions compnsmg the polynucleotide or the polypeptides discussed above or their agonists or antagomsts The polypeptides of the mvention may be employed in combmation with a non-stenle or stenle earner or earners for use with cells, tissues or organisms, such as a pharmaceutical earner suitable for admimstration to a subject Such compositions compnse, for instance, a media additive or a therapeutically effective amount of a polypeptide of the mvention and a pharmaceutically acceptable earner or excipient Such earners may mclude, but are not limited to, saline, buffered saline, dextrose, water, glycerol. ethanol and combinations thereof The formulation should suit the mode of admimstration The mvention further relates to diagnostic and pharmaceutical packs and kits compnsmg one or more containers filled with one or more of the ingredients of the aforementioned compositions of the mvention Polypeptides and other compounds of the mvention may be employed alone or m conjunction with other compounds, such as therapeutic compounds The pharmaceutical compositions may be administered m any effective, convenient manner mcludmg, for instance, admimstration by topical, oral, anal, vaginal, intravenous, intrapentoneal. intramuscular, subcutaneous, lntranasal or mtradermal routes among others En therapy or as a prophylactic, the active agent may be administered to an individual as an mjectable composition, for example as a sterile aqueous dispersion, preferably isotomc Alternatively the composition may be formulated for topical application for example m the form of omtments. creams, lotions, eye ointments, eye drops, ear drops. mouthwash. impregnated dressings and sutures and aerosols, and may contain appropnate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in omtments and creams Such topical formulations may also contam compatible conventional earners, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions Such carriers may constitute from about 1% to about 98% by weight of the formulation, more usually they will constitute up to about 80% by weight of the formulation For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0 01 mg/kg to 10 mg/kg. typically around 1 mg/kg The physician m any event will determine the actual dosage which ill be most suitable for an individual and will vary with the age. weight and response of the particular individual The above dosages are exemplary of the average case There can, of course, be individual mstances where higher or lower dosage ranges are merited, and such are within the scope of this invention In-dwelling devices mclude surgical implants, prosthetic devices and catheters, l e . devices that are mtroduced to the body of an individual and remain in position for an extended time Such devices include, for example, artificial jomts, heart valves, pacemakers, vascular grafts, vascular catheters, cerebrospmal fluid shunts, urinary catheters, contmuous ambulatory pentoneal dialysis (CAPD) catheters The composition of the mvention may be administered by mjection to achieve a systemic effect agamst relevant bacteria shortly before insertion of an m-dwellmg device Treatment may be contmued after surgery during the m-body time of the device In addition, the composition could also be used to broaden peπoperative cover for any surgical techmque to prevent bacterial wound infections, especially Staphylococcus aureus wound infections Many orthopaedic surgeons consider that humans with prosthetic jomts should be considered for antibiotic prophylaxis before dental treatment that could produce a bacteremia Late deep infection is a seπous complication sometimes leadmg to loss of the prosthetic jomt and is accompanied by significant morbidity and mortality It may therefore be possible to extend the use of the active agent as a replacement for prophylactic antibiotics m this situation In addition to the therapy described above, the compositions of this mvention may be used generally as a wound treatment agent to prevent adhesion of bactena to matπx protems exposed m wound tissue and for prophylactic use m dental treatment as an alternative to, or m conjunction with antibiotic prophylaxis Alternatrv ely, the composition of the invention may be used to bathe an mdwellmg device immediateh before insertion The active agent will preferabh be present at a concentration of 1 μg/ml to 1 Omg/ml for bathing of wounds or indwelling devices A composition is conveniently in mjectable form Conventional adjuvants may be emplo\ed to enhance the immune response A suitable unit dose for \accιnatιon is 0 5-5 microgram/kg of antigen, and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks With the mdicated dose range, no adverse toxicological effects will be observed with the compounds of the invention which would preclude their admimstration to suitable individuals Each reference disclosed herem is incorporated by reference herem m its entirety Any patent application to which this application claims priority is also incorporated by reference herem m its entirety EXAMPLES The examples below are earned out usmg standard techniques, which are well known and routine to those of skill in the art, except where otherwise descnbed m detail The examples are illustrative but do not limit the mvention Example 1 Strain selection, Library Production and Sequencing The pohnucleotide having the DNA sequence given in SEQ ID NO 1 was obtained from a library of clones of chromosomal DNA of Staphylococcus aureus m E coh The sequencmg data from two or more clones containing overlapping Staphylococcus aureus DNAs was used to construct the contiguous DNA sequence in SEQ ID NO 1 Libraries may be prepared by routine methods, for example Methods 1 and 2 below Total cellular DNA is isolated from Staphylococcus aureus WCUH 29 according to standard procedures and size-fractionated by either of two methods Method 1 Total cellular DNA is mechanically sheared by passage through a needle m order to size-fractionate according to standard procedures DNA fragments of up to 1 lkbp m size are rendered blunt by treatment with exonuclease and DNA polymerase, and EcoRI linkers added Fragments are ligated into the vector Lambda ZapII that has been cut with EcoRI, the library packaged by standard procedures and E coll infected with the packaged library The library is amplified by standard procedures Method 2 Total cellular DNA is partially hydrolyzed with a one or a combination of restriction enzymes appropriate to generate a series of fragments for clomng into library vectors (e g , Rsal. Pall. Alul, Bshl235I), and such fragments are size-fractionated according to standard procedures EcoRI linkers are ligated to the DNA and the fragments then ligated mto the vector Lambda ZapII that have been cut with EcoRI, the library packaged by standard procedures, and E coll infected with the packaged library The library is amplified by standard procedures Method 3 Total cellular DNA is partially hydrolyzed with a restriction enzyme appropriate for clomng mto a library vector (eg , Sau3A), and such fragments are size fractionated according to standard procedures The fragments are cloned upstream of a reporter gene (e g . the gd resolvase gene tnpR) in a E coli/S aureus shuttle vector (e g , pESAL2) The library is amplified by standard procedures The vector is transformed mto a virulent stram of S aureus (e g , one containing copies of the res sites of gd transposase flanking a kanamycm resistance gene m the chromosome (e g , at the hpase locus)) The pooled constructs are grown in vitro and those bacteria not expressing the reporter gene (e g , excision of the kanamycm gene) are selected for (e g , by kanamycm sensitivity) and collected These pooled bacteria are moculated either mto mice (e g. mtravenously, subcutaneously, etc ) The bactena are recovered from the infected mice after an appropriate time. Those bacteria now expressing the reporter gene are enriched for promoters switched on in vivo, and are selected. The plasmids of these bacteria are recovered and amplified by standard procedures.

Claims: What is claimed is: 1. An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of: (a) a polynucleotide having at least a 70% identity to a polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2; (b) a polynucleotide having at least a 70% identity to a polynucleotide encoding the same mature polypeptide expressed by the clpL gene contained in the Staphylococcus aureus of the deposited strain; (c) a polynucleotide encoding a polypeptide comprising an amino acid sequence which is at least 70% identical to the amino acid sequence of SEQ ID NO:2; (d) a polynucleotide which is complementary to the polynucleotide of (a), (b) or (c); and (e) a polynucleotide comprising at least 15 sequential bases of the polynucleotide of (a), (b) or (c). 2. The polynucleotide of Claim 1 wherein the polynucleotide is DNA. 3. The polynucleotide of Claim 1 wherein the polynucleotide is RNA. 4. The polynucleotide of Claim 2 comprising the nucleic acid sequence set forth in SEQ ID NO: 1. 5. The polynucleotide of Claim 2 comprising nucleotide open reading frame set forth in SEQ ID NO:l. 6. The polynucleotide of Claim 2 which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2. 7. A vector comprising the polynucleotide of Claim 1. 8. A host cell comprising the vector of Claim 7. 9. A process for producing a polypeptide comprising: expressing from the host cell of Claim 8 a polypeptide encoded by said DNA. 10. A process for producing a clpL polypeptide or fragment comprising culturing a host of claim 8 under conditions sufficient for the production of said polypeptide or fragment. 11. A polypeptide comprising an amino acid sequence which is at least 70% identical to the amino acid sequence of SEQ ID NO:2. 12. A polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:2. 13. An antibody against the polypeptide of claim 11. 14. An antagonist which inhibits the activity or expression of the polypeptide of claim 11. 15. A method for the treatment of an individual in need of clpL polypeptide comprising: administering to the individual a therapeutically effective amount of the polypeptide of claim 11. 16. A method for the treatment of an individual having need to inhibit clpL polypeptide comprising: administering to the individual a therapeutically effective amount of the antagonist of Claim 14. 17. A process for diagnosing a disease related to expression or activity of the polypeptide of claim 11 in an individual comprising: (a) determining a nucleic acid sequence encoding said polypeptide, and/or (b) analyzing for the presence or amount of said polypeptide in a sample derived from the individual. 18. A method for identifying compounds which interact with and inhibit or activate an activity of the polypeptide of claim 11 comprising: contacting a composition comprising the polypeptide with the compound to be screened under conditions to permit interaction between the compound and the polypeptide to assess the interaction of a compound, such interaction being associated with a second component capable of providing a detectable signal in response to the interaction of the polypeptide with the compound; and determining whether the compound interacts with and activates or inhibits an activity of the polypeptide by detecting the presence or absence of a signal generated from the interaction of the compound with the polypeptide. 19. A method for inducing an immunological response in a mammal which comprises inoculating the mammal with clpL polypeptide of claim 11, or a fragment or variant thereof, adequate to produce antibody and/or T cell immune response to protect said animal from disease. 20. A method of inducing immunological response in a mammal which comprises delivering a nucleic acid vector to direct expression of clpL polypeptide of claim 11, or fragment or a variant thereof, for expressing said clpL polypeptide, or a fragment or a variant thereof in vivo in order to induce an immunological response to produce antibody and/ or T cell immune response to protect said animal from disease.

Inventors: BEATTIE DAVID T, DERESIEWICZ ROBERT L, HODGSON JOHN E, LONETTO MICHAEL A, LOWE ADRIAN, NICHOLAS RICHARD O, PALMER LESLIE, PRATT JULIE M, BEATTIE, DAVID, T., DERESIEWICZ, ROBERT, L., HODGSON, JOHN, E., LONETTO, MICHAEL, A., LOWE, ADRIAN, NICHOLAS, RICHARD, O., PALMER, LESLIE, PRATT, JULIE, M.
Applicants: BEATTIE DAVID T, BRIGHAM & WOMENS HOSPITAL, DERESIEWICZ ROBERT L, HODGSON JOHN E, LONETTO MICHAEL A, LOWE ADRIAN, NICHOLAS RICHARD O, PALMER LESLIE, PRATT JULIE M, SMITHKLINE BEECHAM CORP, SMITHKLINE BEECHAM PLC, VIRUS RES INST, BEATTIE, DAVID, T., BRIGHAM & WOMEN'S HOSPITAL, DERESIEWICZ, ROBERT, L., HODGSON, JOHN, E., LONETTO, MICHAEL, A., LOWE, ADRIAN, NICHOLAS, RICHARD, O., PALMER, LESLIE, PRATT, JULIE, M., SMITHKLINE BEECHAM CORPORATION, VIRUS RESEARCH INSTITUTE
Application year: 1998
Main classification: C12N1
IPC codes: A61K38, A61K39, A61K45, A61K48, A61P31, C07K14, C07K16, C12N1, C12N5, C12N15, C12P21, C12Q1